How it can be done
As mentioned above, Amarin Corporation Plc is planning to decrease the operating expenses by eliminating around 50% of its staff positions throughout the world. This advice has been provided by the U.S. Food and Drug Administration and Endocrinologic and Metabolic Drugs Advisory Committee. Amarin is still in talks with the Food and Drug Administration regarding the data related to ANCHOR. With the help of this advice, Amarin Corporation Plc thinks that this shift in the staff is the most appropriate course of action which would help in reducing the operating expenses of the organization.
Eliminating of the staff
Amarin Corporation Plc is planning to eliminate 50% of its staff in order to reduce the operating expenses. As a part of the elimination, Amarin Corporation Plc will retain approximately half of its highest performing sales professionals who are available in the targeted geographical areas and who pursue prescription growth of Vascepa in the present condition. This remaining optimized targeted team would be covering the majority of the target base of physicians who are responsible for most of the Vascepa prescription volume and growth. With the help of this optimization and resulting target base, Amarin Corporation Plc anticipates and promises continued Vascepa growth of the revenue with time.
